Goldman Sachs analyst Jamie Perse downgraded Tenet Healthcare to Neutral from Buy with a price target of $140, down from $196. Amid rising policy uncertainty, with a wide range of potential outcomes, Goldman is taking a more cautious view on healthcare providers, the analyst tells investors in a research note. With this view, the firm downgraded hospitals Tenet (THC) and Universal Health (UHS) to Neutral while upgrading Lifestance Health Group (LFST) to Buy, where it believes the company is more insulated from policy risk. For Tenet, the analyst sees policy risk “taking center stage” and likely leaving shares range bound until policy outcomes are better defined, reflected in out year estimates, and in the stock’s valuation.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Block, Five Below downgraded: Wall Street’s top analyst calls
- Tenet Healthcare downgraded to Equal Weight from Overweight at Wells Fargo
- Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz
- Tenet Healthcare downgraded to Outperform from Strong Buy at Raymond James
- Commure to deploy Commure Scribe on Tenet Physician Resources